Artivion (NYSE:AORT) Price Target Raised to $50.00

Artivion (NYSE:AORT) had its price target raised by Canaccord Genuity Group from $41.00 to $50.00 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the stock.

AORT has been the topic of a number of other research reports. JMP Securities lifted their price objective on Artivion from $33.00 to $42.00 and gave the company a “market outperform” rating in a report on Friday, August 8th. Needham & Company LLC lifted their price objective on Artivion from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, August 22nd. Stifel Nicolaus lifted their price objective on Artivion from $36.00 to $40.00 and gave the company a “buy” rating in a report on Friday, August 8th. LADENBURG THALM/SH SH downgraded shares of Artivion from a “buy” rating to a “neutral” rating and lifted their price target for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Artivion in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $43.13.

Artivion Price Performance

Shares of AORT opened at $41.05 on Monday. Artivion has a twelve month low of $21.97 and a twelve month high of $45.07. The stock’s 50 day moving average is $39.98 and its two-hundred day moving average is $31.73. The firm has a market capitalization of $1.94 billion, a PE ratio of -97.74 and a beta of 1.70. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company had revenue of $112.97 million for the quarter, compared to analyst estimates of $107.96 million. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Research analysts anticipate that Artivion will post 0.37 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Jean F. Holloway sold 23,356 shares of Artivion stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $43.01, for a total transaction of $1,004,541.56. Following the completion of the transaction, the senior vice president directly owned 172,129 shares in the company, valued at $7,403,268.29. The trade was a 11.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Marshall S. Stanton sold 18,200 shares of Artivion stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total value of $801,164.00. Following the transaction, the senior vice president owned 64,200 shares of the company’s stock, valued at $2,826,084. This represents a 22.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 74,858 shares of company stock valued at $3,250,129. 7.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of AORT. Legacy Advisors LLC acquired a new position in shares of Artivion during the 1st quarter worth approximately $28,000. MCF Advisors LLC grew its stake in Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after acquiring an additional 614 shares during the period. Smartleaf Asset Management LLC grew its stake in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after acquiring an additional 538 shares during the period. Tower Research Capital LLC TRC grew its stake in Artivion by 447.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company’s stock worth $168,000 after acquiring an additional 4,422 shares during the period. Finally, James Investment Research Inc. purchased a new stake in Artivion in the 2nd quarter worth approximately $210,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.